Acute Kidney Injury and Acute Kidney Disease in COVID-19
Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) in Patients With Coronavirus Disease 2019 (COVID-19)
1 other identifier
observational
900
1 country
1
Brief Summary
Acute kidney injury (AKI) has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of AKI and renal recovery of inpatients diagnosed with COVID-19.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 6, 2020
CompletedFirst Posted
Study publicly available on registry
April 20, 2020
CompletedStudy Start
First participant enrolled
April 21, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 17, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2025
CompletedMarch 6, 2025
March 1, 2025
2.1 years
April 6, 2020
March 3, 2025
Conditions
Outcome Measures
Primary Outcomes (5)
Incidence of AKI
Serial assessment of serum creatinine and urine output
30 days post-hospital admission
Cystatin C as indicator of mortality
All-cause mortality
30 days post-hospital admission
Cystatin C as indicator of renal disease
AKI and acute kidney disease (AKD)
30 days post-hospital admission
Cystatin C as indicator of respiratory illness
Ventilator-free days
30 days post-hospital admission
Cystatin C as indicator of disease severity
Rate of intensive care unit admission
30 days post-hospital admission
Study Arms (2)
ICU patients
Inpatients with COVID-19 requiring ICU care
Non-ICU patients
Inpatients with COVID-19 not requiring ICU care
Eligibility Criteria
Hospitalized patients with diagnosed COVID-19
You may qualify if:
- \) Patients with COVID-19 diagnosed by World Health Organisation (WHO) criteria
You may not qualify if:
- Patients aged less than 18 years
- Patients with stage 4 chronic kidney disease (baseline estimated glomerular filtration rate \<30 ml/min/1.73 m2)
- Patients receiving maintenance dialysis
- Recipients of solid-organ transplantation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Giessen and Marburg, Giessen
Giessen, Hesse, 35382, Germany
Related Publications (1)
Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int. 2020 May;97(5):824-828. doi: 10.1016/j.kint.2020.03.001. Epub 2020 Mar 7. No abstract available.
PMID: 32204907RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Werner Seeger, MD
University Hospital Giessen and Marburg, Giessen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 6, 2020
First Posted
April 20, 2020
Study Start
April 21, 2020
Primary Completion
May 17, 2022
Study Completion
February 1, 2025
Last Updated
March 6, 2025
Record last verified: 2025-03